GiACTA is a Phase III, global, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of subcutaneous Actemra as a novel treatment for GCA. It is the first successful clinical trial ever conducted in GCA and the first to use blinded, variable-dose, variable-duration steroid regimens. The multicenter study was conducted in 251 patients across 76 sites in 14 countries.
The primary endpoint of the study was met; 56% of patients treated with subcutaneous Actemra weekly with a steroid taper phase achieved steroid-free disease remission at one year, versus 14% in the placebo plus 26-week steroid taper group.
The study also met its key secondary endpoint, demonstrating that Actemra combined with a 26-week steroid taper regimen showed superiority in achieving sustained remission at 52 weeks.
No new safety signals were observed and the safety profile of the Actemra groups was generally consistent with the documented safety profile of Actemra in other indications.
In May 2017, the FDA approved Actemra subcutaneous injection for the treatment of GCA. It is the first therapy approved by the FDA for the treatment of adult patients with GCA, and the sixth FDA approval for Actemra since the medicine was launched in 2010.
Actemra is the first humanized interleukin-6 receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs (DMARDs) that did not provide enough relief. It is also used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis or systemic juvenile idiopathic arthritis two years of age and older.
Genentech discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients